Usage Examples
- The treating physician filed an individual patient expanded access request after confirming no comparable therapy was available.
- We are not opening expanded access while the pivotal trial is still enrolling at that site.
- Clinical ops needs the expanded access protocol and the consent form before we agree to supply drug.
What is Expanded Access?
Expanded access is the FDA-authorized use of an investigational drug, biologic, or device to treat a patient outside a clinical trial, permitted only when the disease is serious or immediately life-threatening and no satisfactory alternative therapy exists.
Expanded access exists for the patient the trial cannot reach. Someone with a serious or immediately life-threatening disease, no comparable or satisfactory alternative therapy, and no route into the study that holds the only supply of the product. Rather than leave that patient with nothing, FDA built a treatment route that still runs through the IND framework, so oversight, consent, and safety reporting survive intact.
Expanded access covers investigational drugs and biologics under 21 CFR part 312 subpart I, and investigational devices through a treatment IDE under 21 CFR 812.36, scaling from one named patient up to widespread treatment use. The boundary is that expanded access is treatment, not research. It never substitutes for a trial, and FDA must find that supplying the product will not interfere with the investigations that could support marketing approval.
Expanded access is in practice a sponsor decision before it is a regulatory filing. The sponsor has to agree to supply the product, then either amends its own IND to add the protocol or lets the treating physician submit and reference the sponsor's IND. From there the physician carries investigator obligations, the submitting party carries sponsor obligations, and IRB review, informed consent, and safety reporting apply as they would in a study.
Not to be confused with
- Treatment IND
- a treatment IND is one category of expanded access, the widespread-use one, and FDA grants it only when trial and evidence thresholds are met. Using "treatment IND" as a synonym for all expanded access overstates what a single-patient authorization involves.
- Treatment IDE
- the device analogue, governed by 21 CFR 812.36 rather than part 312. The criteria rhyme, but the submission, the 30-day FDA review clock, and the semi-annual progress reports are device-specific and do not appear in the drug regulations.
- Emergency use
- emergency authorization is a procedure inside individual-patient expanded access, not a separate pathway. FDA can authorize by telephone before anything is written, but the full expanded access submission is still owed within 15 working days.
- A clinical trial
- a trial generates evidence under a protocol designed to answer a question. Expanded access treats a patient and produces safety information as a by-product, which is why it cannot be run as a substitute enrollment channel.
The obligations differ by category, and these are the anchors FDA applies.
What you must do
- 1Establish that the patient has a serious or immediately life-threatening disease or condition and that no comparable or satisfactory alternative therapy is available, before requesting the product21 CFR 312.305(a)(1)
- 2Demonstrate that providing the investigational drug will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval21 CFR 312.305(a)(3)
- 3Limit individual-patient treatment to a single course of therapy for a specified duration unless FDA expressly authorizes multiple courses or chronic therapy21 CFR 312.310(c)(1)
- 4For a treatment IND in a serious disease, support the request with sufficient clinical evidence of safety and effectiveness, ordinarily phase 3 data or compelling data from completed phase 2 trials21 CFR 312.320(a)(3)
- 5For a device, route treatment use through a treatment IDE and show the device is already under investigation in a controlled trial under an approved IDE, or that those trials are complete, with marketing approval actively pursued21 CFR 812.36(b)
Common mistakes
Treating expanded access as something the sponsor cannot refuse
the request runs through an IND the sponsor controls. Without the sponsor agreeing to supply product and to let FDA reference its data, there is nothing for FDA to authorize. Committing to a patient or a physician before the sponsor commits creates a promise the regulatory team cannot keep.
Opening a program while the pivotal trial is still enrolling
FDA must find no interference with investigations that could support approval, so a program that competes with its own trial for patients gets refused or delays the approval that would reach everyone. Sequence expanded access against enrollment status, not against inbound request volume.
Letting an individual-patient authorization run past its scope
the default is a single course of therapy for a specified duration. Continuing to dose, or moving to chronic therapy, without FDA expressly authorizing it puts the physician outside the authorization and the sponsor outside its own protocol.
When This Matters
- The treating physician filed an individual patient expanded access request after confirming no comparable therapy was available.
- We are not opening expanded access while the pivotal trial is still enrolling at that site.
- Clinical ops needs the expanded access protocol and the consent form before we agree to supply drug.
Frequently Asked Questions
Either the sponsor or the treating licensed physician submits it. For a single patient, the sponsor can amend its existing IND to add an expanded access protocol, or the physician can submit after obtaining the sponsor's permission for FDA to reference the sponsor's IND. Without sponsor cooperation, neither route works.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
